MACC1及c-met在前列腺癌中的表达及临床意义  

Expression of MACC1 and C-met in human prostatic cancer and its clinical significance

作　　者：刘洪新[1] 李先佳[2] 沈杰[1] 沈俭[1] 包卫东[1] 陈建华[1] 

机构地区：[1]上海交通大学医学院附属新华医院崇明分院泌尿外科,上海202150 [2]漯河医学高等专科学校基础部,河南漯河462002

出　　处：《现代预防医学》2015年第19期3611-3614,共4页Modern Preventive Medicine

基　　金：上海医药高等专科学校2014年度"飞跃计划"(基金号:2014zr014)

摘　　要：目的探讨前列腺癌组织中结肠癌转移相关基因1(MACC1)及肝细胞生长因子受体(c-met)蛋白的表达及临床意义。方法应用免疫组化方法检测76例前列腺癌组织和16例前列腺增生组织中MACC1及c-met蛋白的表达情况。结果前列腺癌组织中MACC1蛋白阳性率为59.2%,显著高于前列腺增生组织(18.8%),(χ2=8.671,P=0.003);c-met蛋白在前列腺癌组织中阳性率64.5%,显著高于前列腺增生组织(31.2%),(χ2=6.018,P=0.014);随访结果提示MACC1和c-met阳性患者生存率显著低于阴性患者,(χ2=5.480,P=0.019;χ2=14.826,P<0.001);MACC1与c-met蛋白呈正相关。结论 MACC1及c-met蛋白表达增高与前列腺癌的临床分期、病理分级、患者预后密切相关。联合检测MACC1及c-met蛋白可以作为反映前列腺癌的生物学行为的客观指标,有助于判断患者预后。Objective To study expression of MACC1 （ in colon cancer-1） and c-met in prostatic cancer, and explore their clinical pathological significance. Methods The expression of MACC1 and c-met protein was detected by immunohistochemistry in 76 cases of prostatic cancer and 16 cases of hyperplasia of prostate. Results MACC 1 protein positive rate was 59.2% in prostatic cancer, which was significantly higher than that of the hyperplasia of prostate （18.8%）, （χ^2=8.671, P=0.003）. The positive rate of c-met protein in prostatic cancer was 64.5%, which was significantly higher than hyperplasia of prostate （31.2%）, （χ^2=6.018, P=0.014）. The follow-up results showed that positive patients survival rate of MACC1 and c-met were significantly lower than that of negative patients, （χ^2=5.480, P=0.019;χ^2=14.826, P〈0.001）. MACC1 was positively correlated with c-Met. Conclusion MACC1 and c-met protein overexpression were closely related to clinical stage, pathological grade and prognosis of prostatic cancer. MACC 1 and c-met were positive correlated. Combined detection of MACC 1 and c-met can reflect the biologic behavior of prostatic cancer and contribute to judgment the prognosis of the patients.

关 键 词：前列腺癌 结肠癌转移相关基因1 免疫组织化学 

分 类 号：R737.25[医药卫生—肿瘤]